Introduction {#Sec1}
============

The emergence of the novel coronavirus 2019 disease (COVID-19) has caused an international outbreak of respiratory illness that ranges from mild, self-limited disease to severe pneumonia and death \[[@CR1], [@CR2]\]. The rapid spread of the virus outside China despite local and global attempts to restrain dissemination has garnered international attention, and the WHO declared this outbreak a global pandemic in early March 2020 \[[@CR3]\]. Thus far, over one million cumulative cases have been reported worldwide, with a mortality rate of around five percent of cases \[[@CR3]\].

Most patients present with fever, dry cough, and dyspnea in reported cohorts \[[@CR4], [@CR5]\]. Nearly 90% of hospitalized patients have abnormal findings on chest CT \[[@CR5], [@CR6]\], with bilateral ground-glass opacities (GGO) as one of the most common results reported on CT scans of patients with COVID-2019 \[[@CR5], [@CR6]\]. Other manifestations, such as consolidations, lower lobe predilection, and predominantly peripheral distribution of disease, are often reported in CT studies of patients with COVID-2019 \[[@CR7]--[@CR16]\]. In light of these common imaging manifestations, some authors have suggested considering chest CT as a primary tool for detection of COVID-2019 in epidemic areas as many patients have negative reverse transcriptase polymerase chain reaction (RT-PCR) for coronavirus on the initial presentation \[[@CR6]\]. Nonetheless, these imaging findings are not specific to COVID-2019 and could be also be found in other viral pneumonia (e.g., influenza, adenovirus) and non-infectious diseases \[[@CR17]--[@CR39]\]. Furthermore, 6 to 25% of healthy asymptomatic patients can present GGO on chest CT scans, finding which has been described as one of the hallmarks of COVID-2019 \[[@CR40], [@CR41]\].

The aim of this manuscript was to perform a systematic review and meta-analysis of the chest CT findings of COVID-2019 and other viral pneumonia in immunocompetent adults to evaluate if any discriminatory imaging features may help to distinguish COVID-19 from other respiratory viruses.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

This study was reported following Enhancing the Quality and Transparency of Health Research (EQUATOR) Reporting Guidelines, including the Preferred Reporting Items for Systematic Reviews (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. We searched all available literature published in the PubMed-MEDLINE, EMBASE, and Cochrane databases through April 04, 2020. The databases were comprehensibly searched using the terms "pneumonia," "viral," and "imaging" OR "computed tomography." Equivalent terms for each database and detailed search strategy are included in Supplementary File [1](#MOESM1){ref-type="media"}.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Studies were eligible for inclusion if the following criteria were present: (1) subjects had a positive RT-PCR assay in a respiratory tract sample for one of the following viruses: 2019 novel coronavirus (2019-nCoV), adenovirus (AdV), influenza A H1N1; rhinovirus (RNV); parainfluenza virus (PIV); respiratory syncytial virus (RSV); (2) report of chest computed tomography (CT) findings of viral pneumonia, including at least one of the following imaging features: predominant CT pattern or CT findings; (3) cases of acute infections up to 14 days of onset of symptoms; (4) immunocompetent patients ≥ 16 years; (5) design of the study as randomized and non-randomized controlled trials, observational studies, or case series.

To limit heterogeneity, we only included AdV, H1N1, RNV, RSV, and PIV as these were the most prevalent pathogens of viral pneumonia in immunocompetent hosts in previous studies \[[@CR42]--[@CR45]\]. We did not include other influenza A strains, such as H7N9, H5N1, H1N2, and H3N2.

Exclusion criteria were the following: (1) study population that included immunocompromised and did not stratify the analysis from immunocompetent patients; (2) lack of data regarding age and/or immunocompetency status; (3) case reports or series with less than ten subjects, letters to the editor, reviews, or meta-analysis; (4) studies not published in English; (5) studies with animals or in vitro.

Data extraction {#Sec5}
---------------

Two reviewers independently reviewed all included articles to extract data. Disagreements were solved by consensus or with the assistant of a third reviewer with more than 10 years of experience in thoracic radiology. Imaging features were defined following the Fleischner Society's glossary of terms in thoracic radiology \[[@CR46]\].

From each study, we extracted the number of patients presenting the following imaging features: main CT pattern (predominantly or purely GGO; predominantly or purely consolidation; mixed GGO and consolidation; absence of GGO or consolidation), bilateral distribution; axial predominance (central; peripheral; random or diffuse); lobar predominance (upper lobes; middle lobes; lower lobes; random or diffuse (≥ 3 lobes).

Additionally, we also obtained the number of patients presenting the following chest CT findings: GGO, consolidation, nodules (tree-in-bud or centrilobular nodules), interstitial changes (interlobular septal thickening, reticulation, fibrosis), "crazy-paving" pattern, linear opacities, air bronchograms, bronchial wall thickening, vascular enlargement, reverse halo sign, pleural effusion, and mediastinal lymphadenopathy.

We only included data when studies described a per-patient report of the CT findings. As per-lesion analyses could be misleading, we considered the data as "not available" when the authors only described the absolute number of lesions, e.g., the number of GGO lesions. In studies which not all participating patients underwent a chest CT, we considered as the number of patients with a chest CT scan as the study sample size. When multiple publications including the same population was identified from an author group, we only included the most comprehensive study to avoid duplication of data.

Study quality assessment {#Sec6}
------------------------

Two reviewers independently rated the quality of included studies using the National Institutes of Health Quality Assessment Tool for Case Series Studies \[[@CR47]\]. Studies were not excluded due to their quality score to increase transparency and ensure all available evidence in this area was reported.

Statistical analysis {#Sec7}
--------------------

All statistical analyses were performed using Stata version 15.0 (StataCorp LP). We used the Metaprop command to calculate the pooled prevalences of the included variables and their corresponding 95% confidence intervals (95% CI). The *I*^2^ index was used to quantify the extent of heterogeneity. Due to limitations of the meta-analysis of variables with extreme proportions, i.e., zero (0%) or one (100%), the variable was added "n + 1" (in case of 0%) or subtracted "n-1" (in cases of 100%) when appropriate. Random-effects models were used as elevated levels of heterogeneity were expected due to differences in the population and methodology of the articles. We assessed the heterogeneity in main characteristics, including date of publication and study quality.

Results {#Sec8}
=======

Study characteristics {#Sec9}
---------------------

The initial search yielded 2263 studies, from which 96 were reviewed, and 33 met the inclusion criteria. A total of 10 studies on COVID-19 \[[@CR7]--[@CR16]\], and 23 studies on non-COVID viral pneumonias were included (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR17]--[@CR39]\]. Although the article by Ng et al included a 10-year-old child, this patient had a normal chest CT and was removed from this analysis \[[@CR13]\]. A total of 1911 patients were included, of which 934 (48.9%) were in the COVID group and 977 (51.1%) were in the non-COVID group. Summary findings of the studies included in this meta-analysis were presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Methodologic quality was considered fair in all the included studies \[[@CR7]--[@CR39]\]. Publication bias was not able to be assessed due to the heterogeneity in the means of reporting data among different studies. In the non-COVID studies, H1N1 was the main pathogen in 19, AdV in 4, and in one study, there were multiple pathogens in the sample (AdV, H1N1, RSV, and PIV).Fig. 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagramTable 1Main characteristics of COVID pneumonia studies (*n* = 934 patients)StudyPathogenSample sizeMale, no. (%)Age, mean, (SD) \[IQR\], yearsBai et al (2020), ChinaCOVID-19219119 (54.3)44.8 (14.5)Bernheim et al (2020), ChinaCOVID-1912161 (50.4)45.3 (16)Caruso et al (2020), ItalyCOVID-1915883 (52.4)57 \[18--80\]Inui et al (2020), JapanCOVID-1911259 (52.7)60 (17)Li et al (2020), ChinaCOVID-195128 (54.9)58 \[26--83\]Liu et al (2020), ChinaCOVID-197341 (56.2)41.6 (14.5)Ng et al (2020), ChinaCOVID-192013 (61.9)56 \[37--65\]Pan et al (2020), ChinaCOVID-196333 (52.4)44.9 (15.2)Shi et al (2020), ChinaCOVID-196635 (53.0)49.5 (11)Song et al (2020), ChinaCOVID-195125 (49.0)49 (16)*CI*, confidence intervals; *COVID*, coronavirus disease; *IQR*, interquartile range; *SD*, standard deviationTable 2Main characteristics of non-COVID pneumonia studies (*n* = 977 patients)StudyPathogenSample sizeMale, no. (%)Age, mean, (SD) \[IQR\], yearsAmorim et al (2013), BrazilH1N17133 (46.5)41.3 \[16--92\]Cho et al (2011), South KoreaH1N13721 (56.8)46.1 (17.3)Grieser et al (2012), GermanyH1N12316 (69.6)42.2 (16)Henzler et al (2010), GermanyH1N1106 (60.0)45.3 \[27--65\]Hwang et al (2013), South KoreaAdV1111 (100)NAKang et al (2012), South KoreaH1N17642 (55.3)52 \[18--86\]Karadeli et al (2011), TurkeyH1N15221 (40.4)41 (1.3)Kim et al (2011), South KoreaH1N111NA30.7 \[18--79\]Ishiguro et al (2016), JapanH1N12016 (80.0)59.9 (16.4)Lee et al (2012), South KoreaH1N14545 (100)20 \[19--24\]Li et al (2011), ChinaH1N110654 (50.9)31.7 (15.7)Li et al (2011), ChinaH1N12616 (61.5)53 \[40--62\]Marchiori et al (2010), BrazilH1N12011 (55.0)42.7 \[24--62\]Nicolini et al (2012), ItalyH1N12815 (53.6)31.7 \[26--78\]Park et al (2016), South KoreaAdV10498 (94.2)20.1 \[19--24\]Qi et al (2014), ChinaH1N116027 \[22--41\]Shiley et al (2010), USAH1N1, AdV, RSV, PIV185 (27.8)55Sohn et al (2013), South KoreaH1N14121 (51.2)46 \[24--63\]Son et al (2011), South KoreaH1N12013 (65.0)46.5 \[18--69\]Song et al (2011), South KoreaH1N1306 (20.0)36.6 (16.3)Tanaka et al (2011), JapanH1N1106 (60.0)61.3 \[26--85\]Valente et al (2011), ItalyH1N150NA40.9 \[21--76\]Yoon et al (2017), South KoreaAdV152152 (100)21 (2.1)*AdV*, adenovirus; *CI*, confidence intervals; *H1N1*, influenza A H1N1; *IQR*, interquartile range; *NA*, not available; *PIV*, parainfluenza virus; *RSV*, respiratory syncytial virus; *SD*, standard deviation

Pooled prevalence of CT findings {#Sec10}
--------------------------------

Main CT features of COVID-19 and other viral pneumonia are summarized in Table [3](#Tab3){ref-type="table"}. COVID-19 most commonly manifested with either a predominantly GGO pattern (0.42; 95% CI 0.28--0.55) (Fig. [2a](#Fig2){ref-type="fig"}), or a mixed pattern of GGO and consolidation (0.37; 95% CI 0.17--0.56) (Fig. [3a](#Fig3){ref-type="fig"}). Non-COVID viral pneumonia most often presented a mixed pattern of GGO and consolidation (0.46; 95% CI 0.35--0.58) (Fig. [3b](#Fig3){ref-type="fig"}) that was more commonly seen compared with a predominantly GGO pattern (0.25; 95% CI 0.17--0.32) (Fig. [2b](#Fig2){ref-type="fig"}). The predominant consolidation pattern was the least common of both groups (COVID-19, 0.04; 95% CI 0.01--0.07; vs non-COVID, 0.17; 95% CI 0.11--0.23) (Fig. [4](#Fig4){ref-type="fig"}). Heterogeneity was high and significant for all analyses on predominant CT patterns in both groups.Table 3Main CT features of COVID-19 pneumonia compared with other viral pneumoniaImaging featuresCOVID-19Non-COVIDPooled prevalence (95% CI)Pooled prevalence (95% CI)Predominant CT patternPredominantly GGO0.42 (0.28--0.55)0.25 (0.17--0.32)Predominantly consolidation0.04 (0.01--0.07)0.17 (0.11--0.23)Mixed GGO and consolidation0.37 (0.17--0.56)0.46 (0.35--0.58)Absence of GGO or consolidation0.09 (0.04--0.14)0.05 (0.03--0.07)LocationBilateral0.81 (0.77--0.85)0.69 (0.54--0.84)Axial distributionPeripheral0.77 (0.67--0.87)0.34 (0.18--0.49)Random or diffuse0.21 (0.09--0.34)0.50 (0.35--0.65)Lobe involvement (craniocaudal)Upper lobes0.77 (0.65--0.88)0.18 (0.10--0.27)Middle lobes0.61 (0.47--0.76)0.24 (0.11--0.38)Lower lobes0.88 (0.80--0.95)0.61 (0.44--0.78)FindingsGGO0.92 (0.89--0.96)0.80 (0.74--0.85)Consolidation0.47 (0.32--0.63)0.69 (0.61--0.77)Nodules0.14 (0.04--0.24)0.30 (0.19--0.40)Interstitial changes\*0.27 (0.11--0.43)0.27 (0.19--0.35)Pleural effusion0.03 (0.01--0.04)0.25 (0.18--0.32)*CI*, confidence intervals; *COVID*, coronavirus disease; *CT*, computed tomography; *GGO*, ground-glass opacity\*Interlobular septal thickening, reticulation, fibrosisFig. 2Forest plot of the pooled prevalence of "predominantly or purely ground-glass opacity" as the main CT pattern in COVID-19 (**a**) and non-COVID (**b**) studies. This was the most common predominant pattern in patients with COVID-19, and the second most prevalent pattern in non-COVID viral pneumonia. Heterogeneity was high and significant for both COVID-19 and non-COVID studiesFig. 3Forest plot of the pooled prevalence of "mixed ground-glass opacity and consolidation" as the main CT pattern in COVID-19 (**a**) and non-COVID (**b**) studies. This was the most prevalent CT pattern in non-COVID viral pneumonia. Heterogeneity was high and significant for both groupsFig. 4Forest plot of the pooled prevalence of "predominantly or purely consolidation" as the main CT pattern in COVID-19 (**a**) and non-COVID (**b**) studies. This was the least common CT pattern for both COVID-19 and non-COVID patients. Heterogeneity was high and significant for both COVID-19 and non-COVID studies

In both COVID-19 and non-COVID viral pneumonia, chest CT findings were bilateral (COVID-19, 0.81; 95% CI 0.77--0.85; non-COVID, 0.69; 0.54--0.84) (Supplementary Fig. [1](#MOESM1){ref-type="media"}) and most often involved the lower lobes (COVID-19, 0.88; 95% CI 0.80--0.95; non-COVID, 0.61; 0.44--0.78) (Supplementary Fig. [2](#MOESM1){ref-type="media"}). However, COVID-19 pneumonia presented a higher prevalence of peripheral distribution (COVID-19, 0.77; 95% CI 0.67--0.87; non-COVID, 0.34; 95% CI 0.18--0.49) (Supplementary Fig. [3](#MOESM1){ref-type="media"}), and involvement of upper lobes (COVID-19, 0.77; 95% CI 0.65--0.88; non-COVID, 0.18; 95% CI 0.10--0.27) (Supplementary Fig. [4](#MOESM1){ref-type="media"}) and middle lobe (COVID-19, 0.61; 95% CI 0.47--0.76; non-COVID, 0.24; 95% CI 0.11--0.38) (Supplementary Fig. [5](#MOESM1){ref-type="media"}). The most prevalent axial distribution of lesions in non-COVID was a diffuse or random distribution (0.50; 95% CI 0.35--0.65).

GGO was the most common CT finding, found in up to 0.92 (95% CI, 0.90--0.97) of COVID-19 and 0.80 (95% CI, 0.74--0.85) of non-COVID (Supplementary Fig. [6](#MOESM1){ref-type="media"}), followed by consolidation (COVID-19, 0.50; 95% CI 0.33--0.66; non-COVID, 0.69, 95% CI 0.61--0.77) (Supplementary Fig. [7](#MOESM1){ref-type="media"}). Pleural effusion was rare in COVID-19 (0.03; 95% CI 0.01--0.04), but more common in other viral pneumonia (0.25; 95% CI 0.18--0.32) (Supplementary Fig. [8](#MOESM1){ref-type="media"}). A case of COVID-19 presenting the most prevalent CT findings is shown in Fig. [5](#Fig5){ref-type="fig"}. We also present a patient diagnosed with H1N1 and typical images features of COVID-19 (Fig. [6](#Fig6){ref-type="fig"}).Fig. 560-year-old man presenting with typical CT findings of COVID-19 confirmed by RT-PCR. **a** Axial chest CT demonstrates bilateral subpleural ground-glass opacities with superimposed smooth interlobular septal thickening (crazy-paving). **b** Coronal reformatted CT shows bilateral upper to mid lung gradient, though the lower lobes were involved to a lesser extentFig. 631-year-old man with a diagnosis of H1N1. **a**, **b**, **c** Axial chest CT shows multiple subpleural ground-glass opacities and consolidations bilaterally

Discussion {#Sec11}
----------

The most prevalent chest CT findings in patients with COVID-19 were a predominantly GGO pattern (0.42; 95% CI 0.28--0·55), followed by a mixed pattern of GGO and consolidation (0.37; 95% CI 0.17--0.56), bilateral disease (0.81; 95% CI 0.77--0.85), and involvement of the lower lobes (0.88; 95% CI 0.80--0.95). The most prevalent findings in non-COVID viral pneumonia were a mixed pattern of GGO and consolidation (0.49; 95% CI 0.39--0.62), followed by a predominantly GGO pattern (0.25; 95% CI 0.17--0.32), bilateral disease (0.69; 95% CI 0.53--0.85), and involvement of the lower lobes (0.61; 95% CI 0.44--0.78). Compared with other viral pneumonia, COVID-19 demonstrated a higher prevalence of peripheral distribution (0.77; 95% CI 0.67--0.87), and involvement of upper (0.77; 95% CI 0.65--0.88) and middle lobes (0.61; 95% CI 0.47--0.76).

The prevalence of upper and middle zone disease observed in the non-COVID population is likely underestimated. Many authors in this group used the terms "random zone predominance" or "diffuse involvement" referring to patients with involvement of multiple or all lobes, instead of describing which individual lobes were affected \[[@CR17], [@CR18], [@CR23], [@CR34]\]. Thus, patients in these two categories were not included in the analysis of individual lobar distribution, even though some of them possibly had upper and middle zone involvement. All the COVID-19 studies individually described which lobes were affected in their population.

The use of chest CT scan as a primary tool for screening of patients under investigation for COVID-19 is fraught with significant issues \[[@CR48], [@CR49]\]. This approach will result in an increased number of CTs in stable patients that otherwise would not be scanned, leading to increased costs and reduced access to imaging suites, as the entire room would have to be extensively sanitized after every case with suspicion for COVID-19 \[[@CR49], [@CR50]\]. Moreover, the CT scanner may act as a fomite of COVID-19 transmission. Therefore, the American College of Radiology (ACR) urges caution on such approach as a standard CT (especially in the early phases of COVID-19) should not dissuade a patient from viral testing, quarantine, and appropriate treatment \[[@CR51]\]. Also, an abnormal CT should not be seen as diagnostic, as the same pattern may be seen in other viral pneumonia, as demonstrated in this study. Such resemblance should be acknowledged as the COVID-19 emerged simultaneously to the current seasonal influenza in the Northern Hemisphere.

There are two systematic reviews on CT findings on COVID-19 available in the literature with similar results to our study regarding the most common imaging findings in COVID-19 \[[@CR52], [@CR53]\]. Nonetheless, our review differs from those two by not including case series of less than 10 patients, population with pediatric or immunocompromised patients, and studies in which a percentage of the population did not have the diagnosis of COVID-19 confirmed by PCR, such as Ai et al \[[@CR6]\]. We still had high heterogeneity between studies, which could be attributed to several factors. First, chest CT features, such as the predominant imaging pattern, depending on the time course of the infection when the patient is scanned \[[@CR8], [@CR14], [@CR54]\]. A predominant pattern of GGOs is expected in the early course of COVID-19, whereas a mixed pattern often peaks between the second and third week of infection \[[@CR54]\]. To limit this temporal variation of findings, we only included cases of acute infection with up to 14 days of evolution. Another possible cause of inter-study heterogeneity was a non-standard description of the CT findings throughout the studies, which lead to a significant number of missing data. By including only immunocompetent patients, we tried to reduce such heterogeneity of CT findings. Differences in CT scanners and protocols can also be accounted for the high inter-study heterogeneity. Also, the higher prevalence of pleural effusion in non-COVID studies, especially in the studies by Henzler et al and Grieser et al, could be attributed to pulmonary congestion of critically ill patients rather than a common manifestation of viral pneumonia \[[@CR29], [@CR32]\].

Several studies herein discussed have attempted to determine the diagnostic accuracy of chest CT to diagnose COVID-19. However, many are at risk of bias due to methodology limitations, such as lack of a control population and questionable reference tests. As a result, CT estimates of sensitivity and specificity could be flawed \[[@CR55]\]. For instance, Ai et al reported a sensitivity of 97% and suggested chest CT as a primary tool for the detection of COVID-19 in epidemic areas \[[@CR6]\]. Bai et al also found that CT was abnormal in more than 90% of RT-PCR confirmed cases of COVID-19 \[[@CR7]\]. On the other hand, Inui and colleagues described that only 61% of positive cases from Diamond Princess cruise ship had lung opacities on chest CT \[[@CR10]\]. We believe the statistics of the latter comes closer to what would be expected in the general population, especially considering patients who are not very symptomatic and undergo chest CT scanning.

Bai et al investigated the performance of radiologists in differentiating COVID-19 from other viral pneumonia \[[@CR7]\]. The authors found that American radiologists had a surprisingly high accuracy in distinguishing COVID-19 from other viral pneumonia. However, the reproducibility of these findings is questionable, as authors considered as references in the control group patients that had word "pneumonia" in their radiology CT reports and a positive result from respiratory pathogen panel. Also, bilateral GGOs have a much broader differential, present in atypical infections, non-infectious processes, and even in healthy individuals \[[@CR40], [@CR41]\]. Also, some patients with COVID-19 pneumonia may have a normal chest CT scan \[[@CR50]\].

This study has some limitations. First, there were limitations common to any meta-analyses of diagnostic tests (e.g., selection bias, publication bias, missing information). Virtually all studies herein included had a retrospective design, which is also a limitation. The exclusion of studies not available in English could have increased the probability of publication bias. Regarding selection bias, the etiological agents of non-COVID studies were not entirely comprehensible for all viruses associated with community-acquired viral pneumonia (e.g., rhinovirus). Few studies using chest CT in immunocompetent adults are available, as CT imaging is considered "usually not appropriate" by the ACR in this scenario \[[@CR51]\]. Also, the heterogeneity in the results was high due to the reasons discussed above. Finally, the methodology for measuring variables (e.g., axial distribution, predominant CT pattern) was not standardized among manuscripts.

Conclusion {#Sec12}
==========

Except for a higher prevalence of peripheral distribution, involvement of upper and middle lobes, COVID-19, and non-COVID viral pneumonia has overlapping chest CT findings. As such, caution should be exercised when interpreting chest CT for COVID-19 and the use of this imaging modality as a first-line test for COVID-19 diagnosis.

Electronic supplementary material
=================================

 {#Sec13}

ESM 1(DOCX 2.48 mb)

**Publisher's note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors state that this work has not received any funding.

The scientific guarantor of this publication is Bruno Hochhegger, MD, PhD.

The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

One of the authors has significant statistical expertise.

Not applicable since this was a systematic review and did not include information on human subjects.

Not applicable since this was a systematic review and did not include information on human subjects.

• Systematic review and meta-analysis
